Translations:Antihypertensive drug/12/en: Difference between revisions
Jump to navigation
Jump to search
Importing a new version from external source |
Importing a new version from external source |
||
Line 11: | Line 11: | ||
* [[valsartan]] | * [[valsartan]] | ||
* [[Fimasartan]] | * [[Fimasartan]] | ||
In 2004, an article in the [[BMJ]] examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of [[myocardial infarction]] (heart attack). The matter was debated in 2006 in the medical journal of the [[American Heart Association]]. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI. | In 2004, an article in the [[BMJ]] examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of [[myocardial infarction]] (heart attack). The matter was debated in 2006 in the medical journal of the [[American Heart Association]]. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI. |
Latest revision as of 08:24, 4 November 2023
Angiotensin II receptor antagonists

Angiotensin II receptor antagonists work by antagonizing the activation of angiotensin receptors.
In 2004, an article in the BMJ examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of myocardial infarction (heart attack). The matter was debated in 2006 in the medical journal of the American Heart Association. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.